VisiRose Launches Innovative Eye Infection Therapy RB PDAT

VisiRose, a clinical-stage biotechnology company, in collaboration with the Bascom Palmer Eye Institute and Provectus Biopharmaceuticals, has unveiled a novel treatment named Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT). This non-invasive therapy targets infectious keratitis and other severe eye infections. Developed using a combination of Provectus's Rose Bengal Sodium and BPEI's light-based medical technology, RB PDAT addresses infections caused by bacteria, fungi, and parasites.

The therapy is positioned as a potential solution to antimicrobial resistance, offering rapid infection resolution and improved patient outcomes. Clinical trials in multiple countries have shown positive results. RB PDAT caters to the $60 billion global ophthalmic market, focusing on regions affected by antimicrobial resistance and limited treatment access.